Market Overview

Rapid Novor Inc Expands Their Proteomics Lab and Welcomes the 3rd Mass Spectrometer

Share:

Rapid Novor Inc Expands Their Proteomics Lab and Welcomes the 3rd Mass Spectrometer

PR Newswire

KITCHENER, Ontario, Aug. 16, 2018 /PRNewswire-iReach/ -- Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces the expansion of their mass spectrometry facility in Kitchener. With this expansion, the company tripled the laboratory footprints in order to host the newly installed Thermo Fisher Orbitrap Fusion mass spectrometer and the Evosep (www.evosep.com) LC system. The arrival of the new Orbitrap Fusion makes Rapid Novor's lab the largest privately funded proteomics mass spectrometry lab in Southern Ontario.

A year ago, Rapid Novor Inc opened its own mass spectrometry lab in Kitchener. This marked the beginning of the company's accelerated innovation timeline. Since then, the company launched the world's first commercial service, WILD™, to accurately distinguish Isoleucine and Leucine using mass spectrometry, and significantly improved protein sequencing accuracy. During the 12 months period, with the tight communications among protein scientists, mass spec experts, technicians and bioinformaticians, the team more than doubled its REmAb™ antibody protein sequencing throughput by optimizing the experiment conditions, protocols and sequencing algorithms simultaneously.

The new Orbitrap Fusion mass spectrometer supports the advanced EThcD fragmentation, which is critical for the company to further optimizing the WILD™ method and the REmAb™ antibody protein sequencing platform.

"We have built a dream team in proteomics during the past year. But our laboratory instrumentation are at its capacity due to the amount of research work happening here. ", says Mingjie Xie, co-founder and CEO. "The new Orbitrap Fusion mass spectrometer and the Evosep system will not only increase our capacity, but also provide us the new capabilities to do cutting edge research."

"With the increasing demand on the mass spec instrument time, both from customer projects and internal research projects, finding the right balance became more and more challenging.", says Mr. Paul Taylor, Core Facility Manager at Rapid Novor Inc. "The new instruments will give us the much needed wiggle room to meet deadlines both internally and externally. Furthermore, it provides additional tools towards several research project initiatives."

About Rapid Novor Inc.

Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isobaric Isoleucine and Leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor and LinkedIn https://www.linkedin.com/company/rapid-novor-inc/.

Media Contact: Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE Rapid Novor Inc

View Comments and Join the Discussion!